These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25772318)

  • 1. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
    Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
    JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
    Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
    Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low dose nitisinone in the management of alkaptonuria.
    Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
    Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
    Norman BP; Sutherland H; Wilson PJM; Rutland DA; Milan AM; Hughes AT; Davison AS; Khedr M; Jarvis JC; Gallagher JA; Bou-Gharios G; Ranganath LR
    J Inherit Metab Dis; 2024 Jul; 47(4):664-673. PubMed ID: 38487984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of nitisinone in patients with alkaptonuria.
    Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
    Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
    Norman BP; Davison AS; Hickton B; Ross GA; Milan AM; Hughes AT; Wilson PJM; Sutherland H; Hughes JH; Roberts NB; Bou-Gharios G; Gallagher JA; Ranganath LR
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria.
    Curtis SL; Roberts NB; Ranganath LR
    Clin Biochem; 2014 May; 47(7-8):640-7. PubMed ID: 24373924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.
    Ahmad MSZ; Ahmed M; Khedr M; Borgia A; Madden A; Ranganath LR; Kaye S
    JIMD Rep; 2022 Jul; 63(4):351-360. PubMed ID: 35822094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Norman BP; Alsbou M; Imrich R; Gornall M; Sireau N; Gallagher JA; Jackson R
    JIMD Rep; 2022 Jan; 63(1):80-92. PubMed ID: 35028273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adequacy of nitisinone for the management of alkaptonuria.
    Abbas K; Basit J; Rehman MEU
    Ann Med Surg (Lond); 2022 Aug; 80():104340. PubMed ID: 36045846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.